EQT completed the sale of 20 million shares in Galderma Group AG, raising CHF 690 million in gross proceeds. The transaction was part of an accelerated bookbuilding process that generated aggregate gross proceeds of approximately CHF 2.6 billion.
The placement was coordinated by Citigroup, Goldman Sachs, Jefferies, Merrill Lynch, Morgan Stanley, and UBS. EQT received the proceeds as part of its strategy to generate liquidity and redeploy capital.
Galderma Group AG is a Swiss dermatology company that went public on the SIX Swiss Exchange in March 2024. EQT had originally carved out Galderma from Nestlé in October 2019 and held a stake that it has been gradually reducing. The 20‑million‑share sale represents a further divestiture of EQT’s equity stake.
The proceeds will be used for general corporate purposes, including potential investment opportunities and debt reduction, in line with EQT’s stated strategy to strengthen its balance sheet and maintain investment‑grade credit metrics.
EQT Corporation, a leading U.S. natural‑gas producer, reported Q3 2025 results on October 21 2025, with revenue of $1.68 billion and adjusted EPS of $0.52. The company’s production volume was 634 Bcfe and capital expenditures were $618 million. The Galderma sale adds liquidity to EQT’s portfolio and supports its ongoing asset‑sale and capital‑deployment plans.
The CHF 690 million proceeds increase EQT’s cash balance and reduce its net debt, supporting its balance‑sheet strategy and enabling further investment or debt reduction.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.